Fieldview Capital Management, LLC
Position in NAMS — NewAmsterdam Pharma Co N.V.
CIK 2040221
NILES, MI
Position in NAMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,418,025
New position
Shares Held
41,842
first reported quarter
Ownership
0.035%
of shares outstanding
% of Portfolio
0.41%
of 13F equity value
Holder Rank
#103
of 197 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Fieldview Capital Management, LLC holds $10,900,196 across 19 Biotechnology names. NAMS ranks #1 (13.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NAMS |
NewAmsterdam Pharma Co N.V.
This page
|
41,842 | $1,418,025 | |
| 2 | INSM |
INSMED Inc
|
9,748 | $1,039,331 | |
| 3 | ACAD |
Acadia Pharmaceuticals Inc
|
33,368 | $844,210 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
13,930 | $840,814 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
22,883 | $809,829 | |
| 6 | ORKA |
Oruka Therapeutics, Inc.
|
7,104 | $676,087 | |
| 7 | RPRX |
Royalty Pharma plc
|
11,741 | $658,317 | |
| 8 | SYRE |
Spyre Therapeutics, Inc.
|
6,392 | $567,481 |
All Filings in NAMS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,418,025 | 41,842 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||